ATE262924T1 - Streptokokken c5a peptidase impfstoff - Google Patents

Streptokokken c5a peptidase impfstoff

Info

Publication number
ATE262924T1
ATE262924T1 AT97902076T AT97902076T ATE262924T1 AT E262924 T1 ATE262924 T1 AT E262924T1 AT 97902076 T AT97902076 T AT 97902076T AT 97902076 T AT97902076 T AT 97902076T AT E262924 T1 ATE262924 T1 AT E262924T1
Authority
AT
Austria
Prior art keywords
streptococcus
peptidase
vaccine
infection
disclosed
Prior art date
Application number
AT97902076T
Other languages
German (de)
English (en)
Inventor
Paul P Cleary
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of ATE262924T1 publication Critical patent/ATE262924T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/2111—C5a peptidase (3.4.21.110)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT97902076T 1996-01-22 1997-01-21 Streptokokken c5a peptidase impfstoff ATE262924T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/589,756 US5846547A (en) 1996-01-22 1996-01-22 Streptococcal C5a peptidase vaccine
PCT/US1997/001056 WO1997026008A1 (en) 1996-01-22 1997-01-21 STREPTOCOCCAL C5a PEPTIDASE VACCINE

Publications (1)

Publication Number Publication Date
ATE262924T1 true ATE262924T1 (de) 2004-04-15

Family

ID=24359391

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97902076T ATE262924T1 (de) 1996-01-22 1997-01-21 Streptokokken c5a peptidase impfstoff

Country Status (12)

Country Link
US (2) US5846547A (enExample)
EP (1) EP0877624B1 (enExample)
JP (1) JP4361606B2 (enExample)
KR (1) KR100582138B1 (enExample)
AT (1) ATE262924T1 (enExample)
AU (1) AU705732B2 (enExample)
CA (1) CA2243755C (enExample)
DE (1) DE69728380T2 (enExample)
DK (1) DK0877624T3 (enExample)
ES (1) ES2218656T3 (enExample)
PT (1) PT877624E (enExample)
WO (1) WO1997026008A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6676943B1 (en) 1997-04-24 2004-01-13 Regents Of The University Of Minnesota Human complement C3-degrading protein from Streptococcus pneumoniae
CA2317029A1 (en) * 1997-12-31 1999-07-08 Seth H. Pincus A method of isolating a peptide which immunologically mimics microbial carbohydrates including group b streptococcal carbohydrates and the use thereof in a vaccine
KR20010089280A (ko) * 1998-09-24 2001-09-29 리전츠 오브 더 유니버스티 오브 미네소타 스트렙토코쿠스 뉴모니애로부터의 인간 보체 ｃ3 분해폴리펩티드
US7256265B2 (en) * 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
AU1412702A (en) * 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
AU2004226909B2 (en) * 2000-10-27 2008-02-07 J. Craig Venter Institute, Inc. Nucleic acids and proteins from streptococcus groups A & B
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003260102A1 (en) * 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
JP4875490B2 (ja) 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20100015168A1 (en) * 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
US7364291B2 (en) * 2006-06-29 2008-04-29 Johnson & Johnson Vision Care, Inc. Contact lenses with light blocking rings
EP2094297A2 (en) * 2006-10-30 2009-09-02 Novartis AG Immunogenic and therapeutic compositions for streptococcus pyogenes
US20080311129A1 (en) * 2006-11-02 2008-12-18 Camas Incorporated Adherence inhibitor directed to and method of making and using
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
RU2471497C2 (ru) 2007-09-12 2013-01-10 Новартис Аг Мутантные антигены gas57 и антитела против gas57
RU2498994C2 (ru) * 2007-12-21 2013-11-20 Новартис Аг Мутантные формы стрептолизина о
PE20120116A1 (es) 2008-11-05 2012-02-18 Wyeth Llc Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta hemolitica (bhs)
US9095567B2 (en) 2010-06-04 2015-08-04 Wyeth Llc Vaccine formulations
DK3831406T3 (da) 2010-08-23 2024-06-17 Wyeth Llc Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
US9078842B2 (en) * 2011-10-26 2015-07-14 Wisconsin Alumni Research Foundation Peptide for reducing the phosphate requirement and excretion from farm animals
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP2886140A1 (en) * 2013-12-17 2015-06-24 University of Limerick An apparatus for the extracorporeal treatment of blood
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3270959A1 (en) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis compositions and methods thereof
US10544197B2 (en) * 2016-08-12 2020-01-28 Wisconsin Alumni Research Foundation FGF-23 epitope peptide for improving resistance to breakage and eggshell strength
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102871663B1 (ko) 2019-09-27 2025-10-16 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
EP4237428A2 (en) 2020-10-27 2023-09-06 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2022281543A1 (en) 2021-05-28 2023-11-23 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250163977A (ko) 2023-03-30 2025-11-21 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
CN121057590A (zh) 2023-04-14 2025-12-02 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454121A (en) * 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4695562A (en) * 1984-04-06 1987-09-22 Univ. Of Tennessee Research Corp. Synthetic peptide compounds
US4772584A (en) * 1986-05-23 1988-09-20 Cleary Paul P Inhibitor of C5a-mediated chemotaxis
US5162226A (en) * 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5124153A (en) * 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
ATE137672T1 (de) * 1988-03-25 1996-05-15 Univ Rockefeller Vom streptococcus m-protein abgeleitete synthetische peptide und damit hergestellte impfstoffe
EP0672123A1 (en) * 1992-01-08 1995-09-20 The Rockefeller University Multifunctional surface protein of streptococci
WO1993021220A1 (en) * 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
CA2123580C (en) * 1992-09-16 2005-04-26 James B. Dale Antigen of hybrid m protein and carrier for group a streptococcal vaccine
EP0625043B1 (en) * 1992-09-16 2002-03-20 The University Of Tennessee Research Corporation Recombinant multivalent m protein vaccine
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine

Also Published As

Publication number Publication date
DK0877624T3 (da) 2004-06-21
DE69728380T2 (de) 2005-01-27
ES2218656T3 (es) 2004-11-16
JP4361606B2 (ja) 2009-11-11
US5846547A (en) 1998-12-08
US6270775B1 (en) 2001-08-07
KR19990081863A (ko) 1999-11-15
AU1582897A (en) 1997-08-11
AU705732B2 (en) 1999-05-27
EP0877624A1 (en) 1998-11-18
EP0877624B1 (en) 2004-03-31
JP2000513709A (ja) 2000-10-17
WO1997026008A1 (en) 1997-07-24
CA2243755C (en) 2006-10-31
CA2243755A1 (en) 1997-07-24
DE69728380D1 (de) 2004-05-06
PT877624E (pt) 2004-08-31
KR100582138B1 (ko) 2006-08-30

Similar Documents

Publication Publication Date Title
ATE262924T1 (de) Streptokokken c5a peptidase impfstoff
EP1137785B8 (en) STREPTOCOCCAL C5a PEPTIDASE VACCINE
ATE188508T1 (de) Impfstoffe gegen diphtherietoxin
DE69333028D1 (de) Deletionsmutanten als impfstoffe gegen cholera
DK0550477T3 (da) Inaktiveret Mycoplasma hyopneumoniae-bakterin og fremgangsmåde til anvendelse deraf
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
LU91595I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'haemophilus influenzae type b (InfanrixHib)
DE69510858D1 (de) Mukosale Verabreichung von Pneumokokken-Antigenen
AU1362895A (en) Pasteurella multocida toxoid vaccines
HU9801705D0 (en) Streptococcus equi vaccine
Cleary et al. Streptococcal C 5 a peptidase vaccine
MX9604262A (es) Antigenos de pasteurellaceae y vacunas relacionadas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0877624

Country of ref document: EP